Aim: To evaluate the effects of cyproteronacetate/ethinylestradiol (Diane 35) on weight, lipid and androgen levels in women with PCOS.
Methods: 19 PCOS women, age 24.3 +/- 4.3 yrs, weight (W) 66.3 +/- 13.5 kg. Blood samples in the early follicular phase of menstrual cycle for cholesterol (C), HDL cholesterol (HDL-C), triglycerides (TG), testosterone (T), androstenedione (A), DHEAS and SHBG and again after 7 +/- 3.8 months of treatment with Diane 35.
Results: After treatment, W (p<0.05), total C (p<0.05), TG (p<0.004) and SHBG (p<0.0001) increased significantly. Index of free T significantly decreased (p<0.0001). A significant negative correlation between SHBG levels before treatment and increase in the W after Diane was found (r=-0.56; p<0.02). Increase in W correlated negatively with T before treatment (r=-0.58; p<0.02) and positively with the increase in T after treatment (r=0.50; p<0.05). The change in C levels strongly positively correlated with change in TG (r=0.89; p<0.005). Negative relationships between the change in C and DHEAS before treatment (r=-0.76; p<0.05) as well as between the change in TG and DHEAS before treatment (r=-0.73; p<0.05) were found.
Conclusions: Increase in body weight after treatment with Diane 35 abated ameliorating effects of this treatment on androgen levels in PCOS affected women.
Approved by local Ethical committee, supported by grant IGA MZ CR NB/6696-3
08 - 11 Apr 2002
British Endocrine Societies